Latest Prilenia Therapeutics News & Updates

See the latest news and media coverage for Prilenia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Prilenia Therapeutics (Prilenia)

Clinical-stage biotech developing neurodegenerative disease treatments

prilenia.com

Headquarters: Boston, United States
Founded year: 2018
Company type: Private company
Number of employees: 10–70

Last updated Today

Latest news about Prilenia Therapeutics (Prilenia)

In short: Prilenia advanced clinical trials for its lead drug pridopidine and established key partnerships to treat ALS and Huntington’s disease.

Company announcements

May 26 Prilenia

Prilenia donates clinical trial datasets to CHDI Foundation

The data from placebo arms of PRIDE and PROOF studies will advance Huntington's disease research.

May 21 Prilenia

Prilenia Therapeutics' PREVAiLS Phase 3 study unboxed by ALS Society

The study evaluates pridopidine in ALS, with first Canadian patient enrolled and global recruitment across 13 countries.

May 5 Prilenia

Prilenia joins American Biotech Innovation Alliance as founding member

Eric Litjens emphasizes harnessing biotech innovation for economy, healthcare leadership, and patient outcomes in rare neurodegenerative diseases like ALS and Huntington's.

April 28 Prilenia

Prilenia appoints Elisabeth Leiderman as CFO

She brings over 20 years of finance and biotech experience, including fundraising and strategic transactions. The appointment supports Phase 3 studies for HD and ALS.

Media coverage

April 28 Yahoo Finance

Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer

Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and...

April 3 Jammin 99.9

Breakthrough ALS study launches as drug aims to slow disease progression | Jammin 99.9 (WKXB FM)

The “PREVAiLS” study, which will review the investigational drug pridopidine as a potential ALS treatment, has already enrolled its first participant, according to a press...

March 30 Clinical Trials Arena

Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial

Prilenia Therapeutics and Ferrer have enrolled the first participant in the Phase III PREVAiLS trial assessing pridopidine in early ALS.

March 18 PR Newswire

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

Never miss news about Prilenia

Track Prilenia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Prilenia competitors & trending companies

Browse news for competitors to Prilenia and other trending companies.